Hydrocephalus Case Review & Care Pathway Coordination

• Age at diagnosis and suspected cause of hydrocephalus.
• Current symptoms, onset, speed of progression and positional pattern.
• Headache, vomiting, drowsiness, visual change, seizure, gait, balance, cognition, bladder and functional history as relevant.
• Previous episodes of decompensation and the patient’s typical shunt- or ETV-failure symptoms.
• Current neurological, ophthalmological and developmental findings.
• Medication list, anticoagulants, infection history and major medical conditions.

• Current and prior MRI, CT or cranial ultrasound images in DICOM format.
• Radiology reports and dates of each study.
• Images obtained before and after shunt, ETV, tumour surgery, haemorrhage or infection.
• CSF-flow studies or cine MRI where performed.
• Imaging of the full shunt course or abdomen where clinically obtained.
• For suspected NPH: brain imaging suitable for assessment of ventriculomegaly and supportive patterns, together with relevant spine or vascular imaging when part of the differential diagnosis.

Comparison with the patient’s own earlier imaging may be more informative than reliance on a single ventricular measurement.

• Shunt type and route: ventriculoperitoneal, ventriculoatrial, lumboperitoneal or another configuration.
• Manufacturer, valve model, programmable or fixed-pressure status and current documented setting.
• Presence of an antisiphon, gravitational or flow-regulating component.
• Implant card, valve-identification images and most recent setting-confirmation record.
• All previous revision dates, operative reports, failure sites and culture results.
• History of obstruction, disconnection, migration, overdrainage, underdrainage, slit ventricles, pseudocyst or infection.

MRI conditions and post-MRI setting checks are device-specific. The valve model and manufacturer instructions should be confirmed rather than assumed.

• Operative report and date of ETV or ETV with choroid plexus cauterization.
• Hydrocephalus aetiology, age at treatment and prior shunt history.
• Endoscopic findings, stoma description and extent of CPC where applicable.
• Early postoperative imaging and later follow-up studies.
• Any later recurrence, repeat ETV, shunt placement or suspected late failure.
• The emergency instructions previously provided to the patient or family.

• Pregnancy, delivery, prematurity and neonatal intensive-care history.
• Serial head-circumference measurements plotted against age.
• Fontanelle, sutures, eye movements and neurological examination.
• Feeding, growth, motor, language, cognitive and school-development history.
• Associated conditions such as intraventricular haemorrhage, spina bifida, infection, congenital malformation, tumour or epilepsy.
• Therapy, rehabilitation, vision, hearing and educational-support reports.

• Chronology of gait, balance, falls, cognitive and urinary symptoms.
• Standardized gait measures, timed walking tests and pre/post-drainage videos where available.
• Cognitive and functional assessments.
• MRI/CT DICOM and neuroradiology report.
• CSF tap-test, external lumbar drainage, infusion or pressure-monitoring results where performed.
• Assessment of alternative or coexisting causes such as Parkinsonism, cerebrovascular disease, neurodegeneration, neuropathy, arthritis, cervical or lumbar stenosis and urological disease.

• Brain or spinal tumour, cyst, haemorrhage, infection, congenital anomaly or trauma records.
• Pathology, microbiology, oncology and radiation-treatment information where relevant.
• Records of external ventricular drainage, lumbar drainage or temporary CSF access.
• Neurosurgical, neurological, neuroradiological, ophthalmological, rehabilitation and infectious-disease assessments.
• Discussion of whether treatment of the underlying cause may change the CSF-diversion plan.

• Anaesthetic history, bleeding risk, infection risk and wound-healing factors.
• Current stability and whether travel has been medically cleared.
• Family or caregiver availability and accommodation near the treating centre.
• Access to local emergency imaging and neurosurgical care.
• Who can check or reprogramme a valve, review a wound, perform developmental or gait reassessment, and respond to recurrent symptoms.
• Insurance or payment documentation where required for planned treatment.

Enlarged ventricles can occur with active hydrocephalus, long-standing compensated ventriculomegaly, loss of brain volume, congenital anatomy or other conditions. Diagnosis requires clinical–radiological concordance and, in selected situations, physiological testing. Treatment decisions should not rely on one measurement, one scan or the phrase “water on the brain.”

Acute obstructive or decompensating hydrocephalus can require urgent CSF diversion and treatment of the underlying cause. Slowly progressive cases may allow structured diagnostic work-up. Some patients have stable ventriculomegaly without a current indication for surgery but still need clinical and imaging surveillance. International coordination is appropriate only after urgency and travel safety are clarified.

Obstructive hydrocephalus results from a block within the ventricular CSF pathway, for example aqueductal stenosis, a third-ventricular lesion or posterior fossa mass. Communicating hydrocephalus generally reflects impaired CSF absorption after haemorrhage, infection, inflammation or other disease. The distinction informs whether bypassing an obstruction with ETV is plausible or whether another drainage strategy is more appropriate, but real cases may be mixed or more complex than this binary classification.

A tumour, cyst, haemorrhage, infection or structural obstruction may require its own treatment. CSF diversion can be temporary, definitive or staged around treatment of the cause. Removing an obstruction does not always eliminate the need for a shunt, and placing a shunt does not treat the underlying lesion. The sequence should be planned by the treating neurosurgical and multidisciplinary team.

A shunt diverts CSF to another body cavity, most commonly the peritoneum. Choice of entry point, distal site, valve type, pressure strategy and additional flow-control components depends on age, anatomy, aetiology, previous complications and centre practice. No shunt system removes the need for lifelong awareness of malfunction and infection. Programmability can support later adjustment, but it also makes accurate device identification and setting documentation essential.

Shunt problems include proximal or distal obstruction, valve failure, disconnection, fracture, migration, abdominal complications and infection. Symptoms can be non-specific and may differ from one patient to another. A single normal scan or unchanged ventricle size does not necessarily exclude malfunction, particularly in patients with limited ventricular compliance or slit ventricles. Clinical assessment, comparison with baseline imaging and device-specific investigation guide management.

Underdrainage may reproduce symptoms of hydrocephalus. Overdrainage can produce postural headache, subdural collections, slit ventricles or other pressure-related problems. Similar symptoms can also arise from migraine, medication, vision, sleep, autonomic or other neurological conditions. Valve adjustment may be part of management for some programmable systems, but should be performed only by an appropriately trained clinical team after assessment.

ETV creates an internal CSF bypass through the floor of the third ventricle and is most established in selected obstructive hydrocephalus pathways. Suitability depends on anatomy, aetiology, age, previous shunt history, cisternal conditions and surgical assessment. Predictive tools such as the pediatric ETV Success Score can support counselling but do not determine an individual outcome and should not be presented as a guarantee.

ETV avoids a permanent shunt in some patients, but it can fail early or later. Closure of the stoma or failure of CSF absorption can cause recurrent hydrocephalus, including rare rapid deterioration after a period of stability. Patients and families still need lifelong warning-sign education and an emergency plan.

ETV/CPC combines an internal CSF bypass with cauterization of part of the choroid plexus. It may be considered for selected infants in experienced pediatric neuroendoscopy centres. Outcomes vary by age, cause, anatomy, prior treatment, completeness of CPC and centre experience. It is not a universal replacement for shunting and requires the same careful counselling about early and late failure.

In infants and children, ventricular control is only one part of care. Follow-up should consider head growth, vision, hearing, seizures, motor function, cognition, school participation, rehabilitation and the underlying brain condition. Shunt or ETV treatment cannot reverse all effects of prematurity, haemorrhage, infection, malformation or tumour. Transition from pediatric to adult care should include a complete device and surgical history and an emergency plan.

Possible NPH is assessed through the pattern and chronology of gait, cognitive and urinary symptoms together with brain imaging and exclusion of competing causes. The full classic triad is not required in every patient, but gait impairment is usually central to the evaluation. Ventriculomegaly alone is insufficient, and symptoms may be caused or modified by Parkinsonism, cerebrovascular disease, neurodegeneration, neuropathy, arthritis, spinal disease or urological conditions.

Supportive imaging patterns and response to CSF removal can strengthen the case for shunting. Tap testing, external lumbar drainage, infusion studies or pressure monitoring may be used according to specialist practice. A positive response can be useful, while a non-response to one test does not always settle the question. Predefined gait and functional measures improve interpretation.

Shunting for carefully selected NPH patients aims to improve function, commonly with gait as a major outcome. Cognitive and urinary change may be less predictable and coexisting neurodegenerative or vascular disease can limit recovery. Counselling should cover uncertainty, subdural collection or bleeding, infection, obstruction, overdrainage, underdrainage and possible revision. Baseline and follow-up gait, cognition and daily function should be recorded rather than relying only on subjective impressions.

Many modern shunt systems are MRI-conditional, but conditions vary by manufacturer and model. Some programmable valves can change setting in a magnetic field and require confirmation after MRI; others have different specifications. A patient should carry the device name, valve type, current setting, implant date and treating-centre contact. Unknown hardware should not be assumed to be safe or unchanged after imaging.

Patients with possible acute shunt or ETV failure should not travel in place of urgent local assessment. Planned cross-border care requires confirmation of clinical stability, access to original imaging and device records, and a realistic post-treatment emergency plan. Before discharge, the patient and local team should know the procedure performed, shunt model and setting, expected recovery, warning signs, whom to contact and where urgent neurosurgical care is available.